[go: up one dir, main page]

IL156214A0 - New guanidine and amidine derivatives as factor xa inhibitors - Google Patents

New guanidine and amidine derivatives as factor xa inhibitors

Info

Publication number
IL156214A0
IL156214A0 IL15621401A IL15621401A IL156214A0 IL 156214 A0 IL156214 A0 IL 156214A0 IL 15621401 A IL15621401 A IL 15621401A IL 15621401 A IL15621401 A IL 15621401A IL 156214 A0 IL156214 A0 IL 156214A0
Authority
IL
Israel
Prior art keywords
inhibitors
factor
amidine derivatives
new guanidine
guanidine
Prior art date
Application number
IL15621401A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL156214A0 publication Critical patent/IL156214A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15621401A 2000-12-06 2001-11-28 New guanidine and amidine derivatives as factor xa inhibitors IL156214A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126750 2000-12-06
PCT/EP2001/013874 WO2002046159A1 (en) 2000-12-06 2001-11-28 Guanidine and amidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
IL156214A0 true IL156214A0 (en) 2003-12-23

Family

ID=8170585

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15621401A IL156214A0 (en) 2000-12-06 2001-11-28 New guanidine and amidine derivatives as factor xa inhibitors
IL156214A IL156214A (en) 2000-12-06 2003-05-29 History of guanidine and amidine as factor XA inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156214A IL156214A (en) 2000-12-06 2003-05-29 History of guanidine and amidine as factor XA inhibitors

Country Status (26)

Country Link
US (2) US20020173656A1 (et)
EP (1) EP1345900B1 (et)
JP (1) JP4274522B2 (et)
KR (1) KR20040015036A (et)
CN (1) CN1479722A (et)
AR (1) AR033684A1 (et)
AU (2) AU3320602A (et)
BR (1) BR0115938A (et)
CA (1) CA2430518C (et)
CZ (1) CZ20031554A3 (et)
DE (1) DE60126143T2 (et)
DK (1) DK1345900T3 (et)
EE (1) EE200300192A (et)
ES (1) ES2278798T3 (et)
HR (1) HRP20030447A2 (et)
HU (1) HUP0302604A3 (et)
IL (2) IL156214A0 (et)
MX (1) MXPA03004848A (et)
NO (1) NO20032489L (et)
NZ (1) NZ526269A (et)
PL (1) PL362320A1 (et)
PT (1) PT1345900E (et)
RU (1) RU2003120070A (et)
SK (1) SK6862003A3 (et)
WO (1) WO2002046159A1 (et)
ZA (1) ZA200303847B (et)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374971A1 (en) * 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
AU2004263508A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
JP4794303B2 (ja) * 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
ES2324173T3 (es) 2004-12-02 2009-07-31 Prosidion Limited Amidas del acido pirrolopiridin-2-carboxilico.
DE102006048300A1 (de) * 2006-01-26 2007-08-02 Hellstern, Peter, Prof. Dr.med. Inhibitoren des Blutgerinnungsfaktors Xa zur Verwendung als Antikoagulans
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US8507640B2 (en) 2010-08-19 2013-08-13 International Business Machines Corporation Methods of ring opening polymerization and catalysts therefor
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
CN111148743B (zh) 2017-10-06 2023-12-15 福马治疗有限公司 抑制泛素特异性肽酶30
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
SG11202102815SA (en) 2018-10-05 2021-04-29 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (et) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
SI9520044B (sl) * 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
TW542822B (en) * 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
IL133625A0 (en) * 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
BR9909086A (pt) 1998-03-23 2001-09-04 Aventis Pharm Prod Inc Derivados de piperidinila e n-amidinopiperidinila
US20020016339A1 (en) * 1998-03-23 2002-02-07 Klein Scott I. Piperididinyl and N-amidinopiperidinyl derivatives
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
BR0014076A (pt) * 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa

Also Published As

Publication number Publication date
HRP20030447A2 (en) 2005-04-30
KR20040015036A (ko) 2004-02-18
AU3320602A (en) 2002-06-18
PT1345900E (pt) 2007-03-30
DE60126143T2 (de) 2007-11-15
CA2430518A1 (en) 2002-06-13
ES2278798T3 (es) 2007-08-16
ZA200303847B (en) 2004-04-15
DK1345900T3 (da) 2007-05-21
JP4274522B2 (ja) 2009-06-10
IL156214A (en) 2010-05-31
BR0115938A (pt) 2003-12-23
HUP0302604A2 (hu) 2003-11-28
US20020173656A1 (en) 2002-11-21
DE60126143D1 (de) 2007-03-08
RU2003120070A (ru) 2004-12-27
CZ20031554A3 (cs) 2003-08-13
NO20032489L (no) 2003-07-25
NZ526269A (en) 2004-11-26
EP1345900B1 (en) 2007-01-17
CN1479722A (zh) 2004-03-03
SK6862003A3 (en) 2004-02-03
PL362320A1 (en) 2004-10-18
AR033684A1 (es) 2004-01-07
CA2430518C (en) 2010-06-15
NO20032489D0 (no) 2003-06-02
AU2002233206B2 (en) 2006-06-22
US7435747B2 (en) 2008-10-14
HUP0302604A3 (en) 2005-09-28
EE200300192A (et) 2003-08-15
JP2004515492A (ja) 2004-05-27
MXPA03004848A (es) 2003-08-19
WO2002046159A1 (en) 2002-06-13
EP1345900A1 (en) 2003-09-24
US20050143419A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
IL156214A0 (en) New guanidine and amidine derivatives as factor xa inhibitors
AU2003301662A8 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
PT1526132E (pt) Derivados de oxazolidinona substituídos e sua utilização enquanto inibidores do factor xa
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
ZA200306490B (en) Inhibitors of factor Xa.
IL160693A0 (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2001273040A1 (en) Factor xa inhibitors
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PL369855A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
IL185461A0 (en) Pyrimidine compounds and their use
AU2002365896A8 (en) Substituted amino methyl factor xa inhibitors
PL356427A1 (en) Indol-3-yl derivatives and their use as integrin inhibitors
AU2001227122A1 (en) Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
IS5990A (is) Nýjar amidínbensýlamínafleiður og notkun þeirra sem þrombínhemlar
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
IL146731A0 (en) Factor viia inhibitors
IL152396A0 (en) New thiochromane derivatives derivatives and their use as thrombin inhibitors
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
IL153328A0 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU2000229045A1 (en) Benzimidazole derivatives and their use as factor xa inhibitors
SI1150996T1 (sl) Novi amidinobenzilaminski derivati in njihova uporaba kot trombinski inhibitorji
ZA200105277B (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors.